|
|||||
|
|
Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations |
|
| Authors: | Yesid Alvarado MD Hagop M. Kantarjian MD Rajyalakshmi Luthra PhD Farhad Ravandi MD Gautam Borthakur MD Guillermo Garcia‐Manero MD Marina Konopleva MD PhD Zeev Estrov MD Michael Andreeff MD PhD Jorge E. Cortes MD |
| Affiliation: | 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Hemopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| Abstract: | |
| Keywords: | FLT3 inhibitors FLT3‐ITD FLT3‐TKD secondary FLT3 mutations acute myeloid leukemia |